Recombinant Paramyxoviruses Expressing Optimized Heterologous Antigens

The invention pertains to recombinant paramyxoviruses that express one or more heterologous antigens, such as the human respiratory syncytial virus (RSV) F protein, that have been optimized for increased expression and immunogenicity. The recombinant constructs induce a bivalent immune response to the paramyxovirus vectors and the heterologous antigen. Potential vectors include parainfluenza virus (PIV) serotype 1 and 3, Sendai virus, Newcastle disease virus, PIV2, and PIV5. An exemplary modified heterologous antigen includes the ectodomain of RSV F protein linked to the transmembrane and cytoplasmic domains of the F protein from the PIV vector, which results in efficient incorporation into the vector particle. The RSV F ectodomain can be engineered to be stabilized in an optimal conformation, such as the highly immunogenic prefusion conformation. Additionally, the exemplary heterologous RSV F ectodomain can include one or more amino acid substitutions to modify ectodomain expression, conformation, phenotype, or stability.

Potential Commercial Applications: Competitive Advantages:
  • RSV vaccine
  • Paramyxovirus vaccines
  • Prophylactic vaccines
  • Multi-valence
  • Immunogenicity

Development Stage:
  • Early-stage
  • In vitro data available

Related Invention(s):


Jason McLellan (NIAID)  ➽ more inventions...

Barney Graham (NIAID)  ➽ more inventions...

Peter Kwong (NIAID)  ➽ more inventions...

Peter Collins (NIAID)  ➽ more inventions...

Bo Liang (NIAID)  ➽ more inventions...

Shirin Munir (NIAID)  ➽ more inventions...

Anne Nutt (NIAID)  ➽ more inventions...

Ursula Buchholz (NIAID)  ➽ more inventions...

Intellectual Property:
PCT Pat: 10,654,898 issued 2020-05-19
US Application No. 62/105,667 filed on 2015-01-20
US Application No. 15/545,218 filed on 2017-07-20
US Application No. 16/877,319 filed on 2020-05-18

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Jenish Patel at

Licensing Contact:
Peter Soukas, J.D.
Phone: 301-496-2644

OTT Reference No: E-241-2014-0
Updated: Jul 3, 2018